Sample Service
Recommended Information
CD4+ Naive T Cell Sorting Service
CD8+ cytotoxic T cells
CD8+ cytotoxic T cells are considered the primary effector cells of anti-tumor immunity. Their restricted and antigen-specific recognition of tumor-associated antigens (TA) via class I MHC molecules, combined with their ability to produce perforin and other cytotoxins upon activation, enables them to induce tumor cell death while sparing normal cells.
01
Compliance Approval
02
Recruitment and Screening
03
Collect
04
Separation and preparation
05
Cell sorting
06
Quality Control
07
Sample Delivery
01
Compliance Approval
02
Recruitment and Screening
03
Collect
04
Separation and preparation
05
Cell sorting
06
Quality Control
07
Sample Delivery
I. Sample Introduction:
CD8+ cytotoxic T cells are considered the primary effector cells of anti-tumor immunity. Their restricted and antigen-specific recognition of tumor-associated antigens (TA) via class I MHC molecules, combined with their ability to produce perforin and other cytotoxins upon activation, enables them to induce tumor cell death while sparing normal cells.
Delivery method:
| Delivery Specification (million/instance) | Delivery Format |
| 10 / 25 / 50 / 100 | Cryopreservation |
| 25 / 50 / 75 / 100 / 150 / 200 / 300 / 500 / 1000 | Fresh |
Release Criteria:
| Cell count | Cell viability | CD34+ proportion | Bacterial and Fungal Detection (PCR) |
Mycoplasma Detection (PCR) | HAV, HBV, HCV, HIV, TPAb, HTLV, EB, B19 |
| > Specification Quantity | >90% | >90% | Negative | Negative | Negative |
Service Advantages:
Quality System
1. Strict adherence to subject screening , Standards for Sample Collection and Management
2. Complete ethical approval documentation that complies with the review requirements of the ethics committee and other regulatory compliance obligations, including corporate audits, and supports on-site inspections by clients.
3. Professional Cold-Chain Logistics Cooperation system , ensuring the entire sample process Compliant and Efficient Delivery
R&D System
1. Focus in Cell therapy and Gene therapy and large-molecule drug development
2. Continuously optimize standardized preparation processes and lead industry service standards.
3. Innovate service models and expand the boundaries of research applications
Professional Team
1. A seasoned R&D team and a mature, standardized cell preparation process and manufacturing system.
2. Standardization covering both Chinese and international populations Donor Registry and management system
Core Resources
1. World-class production and service equipment, as well as laboratory facilities, nearly 1,000-square-meter R&D base
2. Establish multiple clinical collaboration centers, with the East China region as the leading hub, covering tertiary hospitals nationwide and high-quality GCP management centers.
3. Our in-house specialized project team can provide clients with services such as regulatory interpretation, policy analysis, domestic-investor qualification determination, and approval for foreign-invested cooperation. , Providing one-stop compliance support
II. Sample COA:

Keyword
Previous page:
:Next page
Previous page:
Next page: